Results 21 to 30 of about 151,540 (363)
Drugs in R&D, 2019 Background and objectives Inhibition of Abelson (Abl) tyrosine kinase as a therapeutic target has been gaining attention in neurodegeneration. Post-mortem Alzheimer’s and Parkinson’s disease brains show that the levels of several other tyrosine kinases ...
Alan J. Fowler +7 more
doaj +1 more source
Deep Learning Predicts Prevalent and Incident Parkinson's Disease From UK Biobank Fundus Imaging [PDF]
, 2023 Parkinson's disease is the world's fastest-growing neurological disorder. Research to elucidate the mechanisms of Parkinson's disease and automate diagnostics would greatly improve the treatment of patients with Parkinson's disease. Current diagnostic methods are expensive and have limited availability.
arxiv +1 more source
Atypical parkinsonism: An Update. [PDF]
, 2013 Purpose of review: This update discusses novel aspects on genetics, diagnosis, and treatments of atypical parkinsonism published over the past 2 years. Recent findings: A genome-wide association study identified new genetic risk factors for progressive ...
Hoeglinger, GU, Stamelou, M
core +1 more source
Parkinsonian motor impairment predicts personality domains related to genetic risk and treatment outcomes in schizophrenia [PDF]
, 2017 Identifying endophenotypes of schizophrenia is of critical importance and has profound implications on clinical practice. Here we propose an innovative approach to clarify the mechanims through which temperament and character deviance relates to risk for
Alemán, Gabriela González +15 more
core +2 more sources
EMBO Molecular Medicine, 2013 Tyrosine kinase inhibitors (TKIs) are effective therapies for leukaemia. Alzheimer is a neurodegenerative disease characterized by accumulation of β‐amyloid (plaques) and hyper‐phosphorylated Tau (tangles).
Irina Lonskaya +4 more
doaj +1 more source
Adrenal pheochromocytoma incidentally discovered in a patient with parkinsonism [PDF]
, 2015 To evaluate the diagnostic route of pheochromocytoma (PHEO) in a patient under dopaminergic treatment. A 70-year-old man with Parkinsonism and under treatment with levodopa and carbidopa came to our observation for evaluation of arterial hypertension and
Claudio Letizia +7 more
core +1 more source
Incident mobility disability, parkinsonism, and mortality in community-dwelling older adults.
PLoS ONE, 2021 BackgroundMobility disability and parkinsonism are associated with decreased survival in older adults. This study examined the transition from no motor impairment to mobility disability and parkinsonism and their associations with death.Methods867 ...
Shahram Oveisgharan +3 more
doaj +1 more source
Medium-term prognosis of an incident cohort of parkinsonian patients compared to controls [PDF]
, 2016 Funding This work was supported by Parkinson's UK (grant numbers G0502, G0914), BMA Doris Hillier Award, the BUPA Foundation, NHS Grampian Endowments, RS MacDonald Trust.Peer reviewedPublisher ...
Counsell, C. E. +2 more
core +1 more source
The Lancet, 2021 Parkinson's disease is a recognisable clinical syndrome with a range of causes and clinical presentations. Parkinson's disease represents a fast-growing neurodegenerative condition; the rising prevalence worldwide resembles the many characteristics typically observed during a pandemic, except for an infectious cause.
Bloem, B.R., Okun, M.S., Klein, C.
openaire +2 more sources
Study on drug-induced parkinsonism and its clinical patterns in Eastern Indian population
APIK Journal of Internal Medicine, 2023 Background: Drug-induced parkinsonism (DIP) is important as it is reversible if identified and treated early. We present herewith various clinical patterns and drugs commonly causing DIP.
Praveen Kumar Yadav
doaj +1 more source